Is Cadrenal Therapeutics Inc (CVKD) Stock a Good Investment?
Learn more about Cadrenal Therapeutics Inc's (CVKD) stock grades for Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Commentary & Analysis
Financial Summary
| Share Statistics | CVKD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.9 | $452.3 | 3% |
|
| Shares Out (Mil) | 2.9 | 42.7 | 10% |
|
| Institutional Ownership | 53.0% | 81.2% | 37% |
|
| Float (Mil) | 3.2 | 44.3 | 8% |
|
| Beta | 1.86 | 0.71 | 90% |
|
| Avg Daily Volume (000s) | 346 | 357 | 52% |
|
| Price Change (52-week) |
(92.3%) | 53.8% | 5% |
|
| Growth | CVKD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.4%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.935) | ($3.915) | ($3.405) | |
| Month Ago EPS | ($0.935) | ($3.915) | ($3.405) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($2.100) | ($7.740) | ($3.910) | |
| Year/Year Chg | (18.1%) | (41.0%) | (71.1%) | |
| Financials | CVKD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($11) | 28% |
|
| EPS (TTM) | ($4.864) | ($0.700) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($10) | ($7) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $3 | $493 | 5% |
|
| Valuation | CVKD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.83 | 2.13 | 19% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CVKD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (199.6%) | (22.2%) | 2% |
|
| ROE | (275.2%) | (21.0%) | 3% |
|
| Liabilities to Assets | 26.8% | 32.8% | 18% |
|
| F-Score | 3 | 3 | 18% |
|
Cadrenal Therapeutics, Inc. did not pass any screens on 10/16/2026.
